Cargando…
Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share simil...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874421/ https://www.ncbi.nlm.nih.gov/pubmed/35214708 http://dx.doi.org/10.3390/vaccines10020250 |
_version_ | 1784657684233977856 |
---|---|
author | Boix-Besora, Arnau Lorenzo, Elianet Lavado-García, Jesús Gòdia, Francesc Cervera, Laura |
author_facet | Boix-Besora, Arnau Lorenzo, Elianet Lavado-García, Jesús Gòdia, Francesc Cervera, Laura |
author_sort | Boix-Besora, Arnau |
collection | PubMed |
description | Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants. |
format | Online Article Text |
id | pubmed-8874421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88744212022-02-26 Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 Boix-Besora, Arnau Lorenzo, Elianet Lavado-García, Jesús Gòdia, Francesc Cervera, Laura Vaccines (Basel) Article Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants. MDPI 2022-02-07 /pmc/articles/PMC8874421/ /pubmed/35214708 http://dx.doi.org/10.3390/vaccines10020250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boix-Besora, Arnau Lorenzo, Elianet Lavado-García, Jesús Gòdia, Francesc Cervera, Laura Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title | Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title_full | Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title_fullStr | Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title_full_unstemmed | Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title_short | Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2 |
title_sort | optimization, production, purification and characterization of hiv-1 gag-based virus-like particles functionalized with sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874421/ https://www.ncbi.nlm.nih.gov/pubmed/35214708 http://dx.doi.org/10.3390/vaccines10020250 |
work_keys_str_mv | AT boixbesoraarnau optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2 AT lorenzoelianet optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2 AT lavadogarciajesus optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2 AT godiafrancesc optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2 AT cerveralaura optimizationproductionpurificationandcharacterizationofhiv1gagbasedviruslikeparticlesfunctionalizedwithsarscov2 |